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PRENATAL OPIOID MAINTENANCE IN THE U.S. AND ITS EFFECT ON
NEONATAL ABSTINENCE SYSNDROME: THE CASE OF WEST VIRGINIA’S
OPIOID EPIDEMIC
ABSTRACT
Introduction: West Virginia’s opioid epidemic has been the cause of about 1,000 deaths each
year. Opioid abuse has become an issue among pregnant mothers and has increased the effects
of NAS in infants. The purpose of this research study was to evaluate the participation of
prenatal opioid maintenance to determine if it has decreased the amount of treatment needed for
NAS in infants in WV.

Methodology: The methodology for this study utilized a literature review and a semi-structured
interview. It consisted of academic sources, five electronic databases, academic journals, and
government websites. Thirty-seven sources were referenced for this literature review.

Results: The literature review analyzed opioid maintenance therapy during pregnancy and its
effect on the severity of NAS. It was found that BMT had the most positive effect on NAS after
birth. This review also reported a lack of availability for addicted pregnant women to enroll in
maintenance programs and a high drop-out rate.

Discussion/Conclusion: Opioid maintenance therapy has permitted pregnant women to refrain
from illicit drug use without experiencing withdrawal symptoms and allowed the opportunity for
their infants to have better health after birth. The study reviewed limitations that included the
lack of treatment accessibility and had retractions due to difficulty distinguishing between
generic drug names, databases used, and publication bias. Practical implications included
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continual participation of opioid addicted pregnant women and further research of new
pharmaceuticals.

Key Words: Infants, Maintenance, NAS, Opioid, Pregnant, and WV.

INTRODUCTION
The opioid epidemic in the United States (US) has led to 42,249 overdose deaths per year, and in
West Virginia (WV) it was the cause of 52 per 100,000 deaths (CDC, 2017). In 2017, more than
115 Americans died per day from opioid overdose: the CDC estimated a total of $78.5 billion per
year has been consumed on healthcare due to loss of productivity, addiction treatment, and
criminal justice related to opioid abuse (NIDA, 2018a). Excessive opioid abuse in the US has
increased the occurrence of Neonatal Abstinence Syndrome (NAS) among infants, especially in
WV (Santhanam, 2017).
NAS occurs in infants who have been exposed to opioid usage by drug dependent
mothers throughout pregnancy (Ko, et. al., 2016). NAS has been defined as an opioid
withdrawal syndrome that has been found in 55% to 94% of newborns whose mothers have used
opioid drugs while pregnant (Nair, Soraisham, & Akierman, 2012). It has been caused by the
use of Heroin, Codeine, Oxycodone, Methadone, and Buprenorphine, which has led to health
complications that have commenced within one to three days after birth (Medline Plus, 2017).
The WV state average of children born with NAS was 7.74 per 1,000 births in 2007 and
increased to 31.56 per 1,000 births by 2013, which was three times the national average (Stabler,
et. al., 2017).
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Prenatal drug rehabilitation centers have used Methadone Maintenance Therapy (MMT)
and Buprenorphine Maintenance Therapy (BMT) and has sustained opioid maintenance in
addicted pregnant mothers (Forray, 2016). The Maternal Addiction Recovery Center (MARC)
Program in Huntington, WV at Marshall Obstetrics & Gynecology has offered the combination
of prenatal care and medication maintenance to opioid-addicted pregnant women (Hendricks,
2013). Buprenorphine and Methadone have worked as opioid agonists and have contained
chemicals that have linked to the brain’s opioid receptors and have reduced withdrawal
symptoms from Heroine or other opioids, managed pain, and have created a sense of well-being
(Reuter & Benckiser, 2013). MMT and BMT during pregnancy has stabilized the amount of
opioids within the fetus, decreased the risk of transmitting HIV to the fetus, and has improved
overall neonatal health (NIDA, 2018b). The use of Suboxone has also been implemented during
pregnancy, which has consisted of the combination of Buprenorphine and Naloxone (American
Addiction Centers, 2018). Researchers conducted the Maternal Opioid Treatment: Human
Experimental Research (MOTHER) project, which compared Buprenorphine and Methadone
treatment among opioid addicted pregnant women, and concluded that Buprenorphine has been
the most effective form of treatment for prenatal opioid dependence (Jones, et. al., 2012a).
The purpose of this research study was to evaluate the participation of prenatal opioid
maintenance to determine if it has decreased the amount of treatment needed for Neonatal
Abstinence Syndrome in infants in West Virginia.
METHODOLGY
The primary hypothesis for this study was that opioid maintenance therapy among pregnant
women has decreased the occurrence and severity of NAS in infants. The methodology for this
research analysis utilized a literature review of academic sources. The conceptual framework,
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illustrated by Figure 1, showed an adaptation of the research framework by Brogly, Hahn, Diaz,
& Werler, 2015, which demonstrated the benefits and barriers to opioid maintenance treatment
during pregnancy. The use of this framework was appropriate because it demonstrated the
adoption of MMT and BMT within prenatal drug treatment programs. It was similar to any
project development in that the process was circular; it began with identification and definition
of the opioid crisis and included development solutions. In this case, the solution has been
preventing illicit drug usage or withdrawal during pregnancy through the use of maintenance
medications to reduce NAS severity. Through process assessment, the use of opioid maintenance
among pregnant women was researched, and the statistics showed positive effects on the infants
after birth. Once prenatal drug treatment programs implemented the usage of medicatedmaintenance therapy, benefits and barriers were addressed (Figure 1).

The literature review was conducted in three individual stages involving: (1) developing a search
strategy and gathering data for the case study; (2) determining and analyzing the relevant
literature; (3) delegating literature to appropriate categories.

Step 1: Literature Identification and Collection

The electronic databases used include JAMIA, Elibrary, PubMed, Medline, and Google Scholar.
The terms searched within each database were: “prenatal drug programs” AND “opioid
maintenance” OR “opioid therapy” AND “Neonatal Abstinence Syndrome” OR “NAS” OR
“neonatal withdrawal syndrome” AND “WV” OR “US”. Journals cited included: The Journal of
the Medical Library Association, West Virginia Medical Journal, The Journal of Rural Health,
Journal of Addiction Research & Therapy, and other reliable medical and government websites.
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Step 2: Literature Analysis

As the US and WV opioid crisis has continued to rise, it has become important to know its
impact on pregnant women and their infants. Therefore, the literature analyzed focused on the
following key areas: the utilization MMT and BMT, opioid maintenance completion, and
severity of NAS after treatment has been administered. In attempt to collect the most recent data,
sources preceding years 2008-2018 were removed from the search and only sources written in
English were used. Primary and secondary data from articles, literature reviews, research studies,
and reports written in the US were included in this research. The literature review included 37
references which were assessed for information pertaining to this research project. Furthermore,
a semi-structured interview with an expert Nurse Coordinator of prenatal opioid maintenance
supplemented information to the data collected. The Nurse Coordinator will be referred to as
Expert in Prenatal Opioid Maintenance throughout the review. The interview was tape recorded
and IRB approval was obtained prior to execution. The literature search was conducted by MR
and validated by AC, who acted as second reader and also double checked if references met the
research study inclusion criteria.

Step 3: Literature Categorization

The following subheadings were included in part of the following research framework: Illicit
Opioid Use During Pregnancy in the US and WV, Infants with NAS in the US and WV, MMT
and BMT During Pregnancy, and Prenatal Opioid Maintenance Programs.
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RESULTS
Illicit Opioid Use During Pregnancy in the US and WV
From 2008-2012, approximately 39.4% of female Medicaid patients and 27.7% of
privately insured patients that were of childbearing age (15-44 years old) received opioid
prescriptions each year (Krans & Patrick, 2016). These researchers also stated that out of more
than 1 million Medicaid patients, 21.6% of pregnant women filled an opioid prescription and
2.5% of prescriptions exceeded 30 days. In 2011, 5% of women ages 15-44 years old in the US
used illicit drugs while pregnant (Whiteman, et. al., 2014). In addition, 138,224 out of
55,781,965 hospitalizations among pregnant women were due to opioid abuse. More than 35%
of opioid dependent women have also tested positive for marijuana, cocaine, benzodiazepines,
and 77%-95% and have smoked tobacco (Krans, Cochran, & Bogen, 2015).
A study conducted in 2009 reported that 146 out of 759 pregnant women in WV, or
19.2% tested positive for drug or alcohol abuse (Stitely, Calhoun, Maxwell, Nerhood, & Chaffin,
2010). In 2010, 1 out of 3 pregnant women positively tested for opioid abuse at Charleston Area
Medical Center’s (CAMC) Women’s Medicine Center in Charleston, WV, but increased to 37%
percent during the first quarter of 2011. Furthermore, CAMC tested 706 pregnant mothers
between July 2010 and July 2011, which showed usage of 74% marijuana, 20% opioid, 12%
Benzodiazepines, and 6% Methadone (Harold, 2011).
Infants with NAS in the US and WV
Infants that have been born with NAS in the US more than doubled between years 2009
and 2013, with an increased rate of 3.6 per 1,000 infants to a rate of 7.3 per 1,000 (Brown,
Doshi, Pauly, & Talbert, 2016). One study stated that in 2012, US hospitals expended $316
million on infants with NAS, whose average length of stay was 16.6 days, or 3.5 times more than

6

Morgan Ruley – Final Draft – April 30, 2018 – HCA 695 – Dr. Coustasse
a non-NAS infant (Corr & Hollenbeak, 2017). Drug dependent infants in the US have had a
150% greater chance of being readmitted into the hospital within 30 days after birth than infants
born without any health complications (IDPH, 2017). Medicated-maintenance has been utilized
to treat withdrawal symptoms in 50%-70% of infants born with NAS (Krans, Cochran, & Bogen,
2015).
In 2016, the frequency of NAS among infants in WV was approximately 5% of total
births (Holdren, 2017). This author also stated an increase from the two previous years, with 32.1
per 1,000 infants born with NAS in 2014 and 34.4 per 1,000 in 2015. Another report in 2017
suggested that newborns with NAS were born every 25 minutes in WV (LeBeau, 2017). In
2013, 108 per 1,000 infants in Huntington, WV, were born with NAS, compared to the statewide
amount of 37 per 1,000 and the nationwide rate of 7 per 1,000 (Davis, 2016). Four years later at
Cabell Huntington Hospital in Huntington, WV, 140 per 1,000 infants were born with NAS,
compared to the national average of 6 per 1,000 newborns (Lofton, 2017).
According to WV perinatal collaborative officials, 33.3% of infants with NAS have been
treated in well newborn nurseries, while the remaining 66.7% have been treated special care
nurseries or the Neonatal Intensive Care Unit (NICU). Furthermore, drug dependent infants
have cost an average daily charge of $400 in WV’s neonatal withdrawal centers, $2,600 in a
special care nursery, and $4,000 in a NICU (GAO, 2017). A study conducted by West Virginia
University suggested that the average length of stay for newborns with NAS was 18 days, which
resulted in an overall hospitalization cost of $9,000-$12,600 (Towner, 2017). Lily’s Place, an
extended NAS treatment facility in Huntington, WV, has kept infants for 2 weeks to 12 months
for addiction withdrawal treatment but only has 12 available beds: they have treated 91 infants
since opening in 2014 (Davis, 2016).
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Methadone and Buprenorphine Maintenance Therapy During Pregnancy
According to the MOTHER, infants whose mothers participated in MMT during
pregnancy had a hospital stay extent of 15-20 days and NAS treatment duration of 10 days,
whereas infants whose mothers used BMT had a hospital stay of 10 days and NAS treatment
duration for less than 5 days (Whitten, 2012). Researchers have suggested that within 4 weeks of
the being transitioned from MMT to BMT, 15% of women showed illegal drug usage in urine
screening, 90% continued follow-up appointments until delivery of the child, and 38.9% did not
use drugs illicitly at the time of delivery (Johnson & Martin, 2017). Furthermore, there were
fewer cases of NAS and shorter hospitals stays after birth when transitioned from MMT to BMT.
A recent study showed that BMT, rather than single-methadone treatments, has shown a
10% lower chance of NAS, 8.4 fewer days of neonatal treatment, and 3.6 mg less Morphine
treatment (NIDA, 2018c). BMT has shown a longer duration of movements and less suppression
in motor activity in infants (Jones, et. al., 2012b). Researchers from WVU reported that 81% of
infants who have been exposed to MMT still needed treatment for NAS, while only 26% who
were exposed to BMT required NAS treatment (Nanda, Brant, Regier, & Yossuck, 2015). In a
study that involved 716 women participating in MMT or BMT, infants whose mothers were
exposed to MMT showed a 65% incidence of NAS, whereas those exposed to BMT showed 49%
(Lemon, et. al., 2018). This study also showed 17 more cases of NAS when mothers participated
in MMT rather than BMT.
Prenatal Opioid Maintenance Programs
The MARC Program in Huntington, WV has the capacity to treat 36 patients, which have
ranged from ages 22-34 years of age (Expert in Prenatal Opioid Maintenance, 2018). However,
upon the occasion that MARC has been unable to treat anymore patients, they have contacted an
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alternate facility and placed them on their waiting list. The Expert in Prenatal Opioid
Maintenance stated that drug tests, which have included urine and blood screenings, have been
performed weekly. Furthermore, if drugs screenings were not clear, a breach in contract has
occurred, and patients must discontinue treatment. The Expert reported that Buprenorphine has
been administered to MARC patients during the term of pregnancy at a maximum dose of 16 mg
per day. After delivery, however, patients have been prescribed Suboxone, which also has a
maximum dose of 16 mg per day. Each patient has been prescribed a different dose depending
on each individual’s level of addiction and have experienced minimal side effects such as nausea
or headaches (Expert in Prenatal Opioid Maintenance, 2018). In addition to medication, the
Expert also stated that patients have been required to attend group counseling, monthly
individual meetings, and two Narcotics Anonymous meetings per month. The Expert reported
that there have not been any cases of overdose while participating in the MARC Program.
One study in 2017 stated that only 16% of drug dependent pregnant women have
successfully completed an opioid maintenance program and sustained from illicit drug use until
the time of delivery (Klaman, et. al., 2017). Researchers have found that the dropout rate of
mothers who used Buprenorphine as maintenance medication was 33%, which was significantly
higher than the 18% dropout rate of pregnant women who used Methadone during maintenance
therapy (Stover & Davis, 2015). Between the years of 1992-2012, the number of pregnant
women who were admitted into prenatal opioid therapy facilities due to prescription opioid drug
usage increased from 2% to 28% (Krans & Patrick, 2016). Finally, a study that consisted of 95
women showed that 44% relapsed and resorted to illicit drug use before giving birth (Krans,
Cochran, & Bogen, 2015).
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DISCUSSION
The purpose of this research study was to evaluate the participation of prenatal opioid
maintenance to determine if it has decreased the amount of treatment needed for Neonatal
Abstinence Syndrome in infants. The primary hypothesis for this study was that opioid
maintenance therapy among pregnant women has decreased the occurrence and severity of NAS
in infants. This analysis showed that prenatal opioid maintenance, especially with the use of
Buprenorphine, has decreased the need for NAS treatment after birth and increased overall health
in infants born to mothers who have participated in medication maintenance therapy.
One study showed that 5% of women within child bearing ages illicitly used opioids
during their term of pregnancy (Whiteman, et. al., 2014). In WV, the amount of opioid-addicted
pregnant women has continued to increase each year: this has resulted in more than twice as
many cases of NAS. Hospitals have expended over $300 million to treat infants with NAS,
which have required 3.5 longer hospital stays than healthy newborns due to medicatedmaintenance and health complications (Corr & Hollenbeak, 2017). Holdren, 2017 suggested that
NAS occurred in 5% of total births in WV in 2016, which has shown a continual increase each
year. Cabell Huntington Hospital in Huntington, WV, had 134 more cases of NAS per 1,000
newborns than the remainder of hospitals in the state.
Studies have shown that BMT throughout pregnancy has been more effective for NAS
after delivery than MMT. Johnson & Martin, 2017 reported less cases of NAS and a shorter
length of stay with BMT. Furthermore, another study found that a significant amount of MMT
exposed infants still needed treatment, compared to those who were exposed to BMT (Lemon, et.
al., 2018). The MARC Program in Huntington, WV has had a 100% completion rate using
BMT, with minimal side effects. After delivery, MARC patients have been prescribed Suboxone
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for maintenance. Patients have also attended counseling and meetings as supplementary forms
of treatment (Expert in Prenatal Opioid Maintenance, 2018). On the contrary, Klaman, et. al.,
2017 reported only 16% of women have completed a program without returning to illicit drug
use. Furthermore, the need for prenatal opioid maintenance has continued to increase. Between
1992-2012, the need for medication maintenance increased by 26% (Krans & Patrick, 2016).
A positive component of opioid maintenance therapy throughout the term of pregnancy in
WV and the US has been the decrease in necessary treatment and severity of NAS in infants after
birth. BMT has decreased the occurrence of NAS in infants to 49% and has decreased treatment
needed for those born with NAS.
A negative component to prenatal opioid maintenance has been the dropout or relapse
rate of pregnant mothers. Prenatal opioid maintenance programs also have not had the capacity
to treat every opioid-addicted pregnant mother that has been seeking medication maintenance
therapy.
Limitations
This research study was not conducted without its limitations. Prenatal opioid
maintenance programs have not had the capacity for all pregnant mothers who have needed
treatment, which has resulted in NAS severity among infants. This literature review was
restricted due to search strategy such as difficulty distinguishing generic drug names, number of
databases or sources found, which may have affected the availability or accuracy of the research,
and finally research and publication bias. Further research of Buprenorphine, Methadone, or
new drugs is needed to ensure better results of NAS occurrence in the future.
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Practical Implications
Continual participation in maintenance medication and cooperation of opioid-addicted
pregnant women will help with further research regarding the occurrence and severity of NAS in
newborns. BMT has decreased the need for opioid treatment in infants after birth and improved
their overall health. The practical implications of prenatal opioid maintenance outcomes will
need to be more heavily researched as more pregnant mothers continue to participate or drop-out
of programs and new drugs come into the market.
CONCLUSION
Participation in opioid maintenance therapy during pregnancy has shown a decrease in severity
of NAS infants. This literature review has suggested that BMT has been the most effective form
of treatment thus far.
SEMI-STRUCTURED INTERVIEW
Lindsey, Nikki. MARC Program Nurse Coordinator. Marshall OBGYN. March 20, 2018.
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Promote Participation of Prenatal Opioid Maintenance Therapy

Benefits
US Opioid
Crisis

NAS
Severity

MMT and
BMT

Maintenance
Programs

Barriers

Source: Adopted from (Brogly, Hahn, Diaz, & Werler, 2015)
Figure 1: Conceptual Research Framework
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APPENDIX A
Questions Asked in Semi-Structured Interview of an Expert in Prenatal Opioid Maintenance on
March 20, 2018
•

What is your rate of relapse?

•

How often have patients become opioid-free by the time of delivery? Why?

•

How frequently do you perform drug tests?

•

What is the range of ages currently enrolled? Why?

•

Does a certain age group have a higher completion rate? Why?

•

How many women can you have enrolled at once?

•

How many women do you have to turn away? Why?

•

What are the requirements/repercussions of staying in the program?

•

What maintenance medication do you use? Why?

•

How often is medication administered? Why?

•

If more than one form of treatment is used, have you found one to be more effective than
the other? Why?

•

What are the side effects of medication used for treatment?

•

How many miscarriages have been reported?

•

Have any women overdosed while participating in your program?

•

If known, how has your program impacted the infants of your patients? Why?
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